Selective serotonin reuptake inhibitors use and the risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with one million participants

Eur J Clin Pharmacol. 2022 Jul;78(7):1199-1200. doi: 10.1007/s00228-022-03309-y. Epub 2022 Mar 11.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Hepatocellular* / epidemiology
  • Cohort Studies
  • Humans
  • Liver Neoplasms* / chemically induced
  • Liver Neoplasms* / epidemiology
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Serotonin and Noradrenaline Reuptake Inhibitors*
  • Systematic Reviews as Topic

Substances

  • Serotonin Uptake Inhibitors
  • Serotonin and Noradrenaline Reuptake Inhibitors